ASCO 2025
May 30 - June 3, 2025 | Chicago, IL
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Presentation
Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study.EP Hamilton et al.